메뉴 건너뛰기




Volumn 68, Issue 2, 2013, Pages 404-408

Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: A cohort study

Author keywords

Adverse effects; Antiretroviral therapy; Creatine kinase elevation; HIV; Raltegravir

Indexed keywords

CREATINE KINASE; RALTEGRAVIR; VIRUS RNA;

EID: 84872424632     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks416     Document Type: Article
Times cited : (17)

References (29)
  • 1
    • 67149138180 scopus 로고    scopus 로고
    • Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era
    • Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol 2009; 21: 404-10.
    • (2009) Curr Opin Rheumatol , vol.21 , pp. 404-410
    • Nguyen, B.Y.1    Reveille, J.D.2
  • 3
    • 49849103584 scopus 로고    scopus 로고
    • Severe rhabdomyolysis associated with raltegravir use
    • Zembower TR, Gerzenshtein L, Coleman K et al. Severe rhabdomyolysis associated with raltegravir use. AIDS 2008; 22: 1382-4.
    • (2008) AIDS , vol.22 , pp. 1382-1384
    • Zembower, T.R.1    Gerzenshtein, L.2    Coleman, K.3
  • 4
    • 75649112262 scopus 로고    scopus 로고
    • A case of rhabdomyolysis associated with raltegravir use
    • Dori L, Buonomini AR, Viscione M et al. A case of rhabdomyolysis associated with raltegravir use. AIDS 2010; 24: 473-5.
    • (2010) AIDS , vol.24 , pp. 473-475
    • Dori, L.1    Buonomini, A.R.2    Viscione, M.3
  • 5
    • 77955049938 scopus 로고    scopus 로고
    • Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution
    • Masiá M, Enríquez R, Sirvent A et al. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect 2010; 61: 189-90.
    • (2010) J Infect , vol.61 , pp. 189-190
    • Masiá, M.1    Enríquez, R.2    Sirvent, A.3
  • 6
    • 78650825831 scopus 로고    scopus 로고
    • Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature
    • Croce F, Vitello P, Dalla Pria A et al. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. Int J STD AIDS 2010; 21: 783-5.
    • (2010) Int J STD AIDS , vol.21 , pp. 783-785
    • Croce, F.1    Vitello, P.2    Dalla Pria, A.3
  • 7
    • 84857239027 scopus 로고    scopus 로고
    • Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (27 June, date last accessed)
    • Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http:// www.aidsinfo.nih.gov/ContentFiles/vguidelines/AdultandAdolescentGL. pdf (27 June 2012, date last accessed).
    • (2012) Panel on Antiretroviral Guidelines for Adults and, Adolescents
  • 8
    • 44949194170 scopus 로고    scopus 로고
    • European AIDS Clinical Society (EACS). Version 6.0 (October 2011). (27 June date last accessed)
    • European AIDS Clinical Society (EACS). Guidelines for clinical management and treatment of HIV-infected adults in Europe. Version 6.0 (October 2011). http://www.europeanaidsclinicalsociety.org/images/stories/ EACS-Pdf/EACSguidelines-v6.0-English.pdf (27 June 2012, date last accessed).
    • (2012) Guidelines for clinical management and treatment of HIV-infected adults in Europe
  • 9
    • 77954348583 scopus 로고    scopus 로고
    • Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
    • Martínez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24: 1697-707.
    • (2010) AIDS , vol.24 , pp. 1697-1707
    • Martínez, E.1    Larrousse, M.2    Llibre, J.M.3
  • 10
    • 63649087422 scopus 로고    scopus 로고
    • Raltegravir: the first HIV type 1 integrase inhibitor
    • Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48: 931-9.
    • (2009) Clin Infect Dis , vol.48 , pp. 931-939
    • Hicks, C.1    Gulick, R.M.2
  • 11
    • 84896503763 scopus 로고    scopus 로고
    • Role of raltegravir in the management of HIV-1 infection
    • Okeke NL, Hicks C. Role of raltegravir in the management of HIV-1 infection. HIV AIDS 2011; 3: 81-92.
    • (2011) HIV AIDS , vol.3 , pp. 81-92
    • Okeke, N.L.1    Hicks, C.2
  • 12
    • 80052905594 scopus 로고    scopus 로고
    • Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK
    • Rockstroh JK, Lennox JL, Dejesus E et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53: 807-16.
    • (2011) Clin Infect Dis , vol.53 , pp. 807-816
    • Rockstroh, J.K.1    Lennox, J.L.2    Dejesus, E.3
  • 13
    • 84865623088 scopus 로고    scopus 로고
    • Tolerability of integrase inhibitors
    • Lee FJ, Carr A. Tolerability of integrase inhibitors. Curr Opin HIV AIDS 2012; 7: 422-8.
    • (2012) Curr Opin HIV AIDS , vol.7 , pp. 422-428
    • Lee, F.J.1    Carr, A.2
  • 14
    • 2542496096 scopus 로고    scopus 로고
    • Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count
    • García F, de Lazzari E, Plana M et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr 2004; 36: 702-13.
    • (2004) J Acquir Immune Defic Syndr , vol.36 , pp. 702-713
    • García, F.1    de Lazzari, E.2    Plana, M.3
  • 15
    • 33644960500 scopus 로고    scopus 로고
    • Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients
    • Gratacòs L, Tuset M, Codina C et al. Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients. Med Clin 2006; 126: 241-5.
    • (2006) Med Clin , vol.126 , pp. 241-245
    • Gratacòs, L.1    Tuset, M.2    Codina, C.3
  • 16
    • 34247850998 scopus 로고    scopus 로고
    • Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area
    • Martínez E, Milinkovic A, Buira E et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 2007; 8: 251-8.
    • (2007) HIV Med , vol.8 , pp. 251-258
    • Martínez, E.1    Milinkovic, A.2    Buira, E.3
  • 17
    • 47949120697 scopus 로고    scopus 로고
    • Raltegravir with optimized background therapy for resistant HIV-1 infection
    • Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-54.
    • (2008) N Engl J Med , vol.359 , pp. 339-354
    • Steigbigel, R.T.1    Cooper, D.A.2    Kumar, P.N.3
  • 18
    • 75749107023 scopus 로고    scopus 로고
    • Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
    • Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50: 605-12.
    • (2010) Clin Infect Dis , vol.50 , pp. 605-612
    • Steigbigel, R.T.1    Cooper, D.A.2    Teppler, H.3
  • 19
    • 77949381837 scopus 로고    scopus 로고
    • Long term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study
    • Gatell JM, Katlama C, Grinzstejn B et al. Long term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J Acquir Immune Defic Syndr 2010; 53: 456-63.
    • (2010) J Acquir Immune Defic Syndr , vol.53 , pp. 456-463
    • Gatell, J.M.1    Katlama, C.2    Grinzstejn, B.3
  • 20
    • 70350558421 scopus 로고    scopus 로고
    • Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection
    • Markowitz M, Nguyen BY, Gotuzzo E et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52: 350-6.
    • (2009) J Acquir Immune Defic Syndr , vol.52 , pp. 350-356
    • Markowitz, M.1    Nguyen, B.Y.2    Gotuzzo, E.3
  • 21
    • 81855166275 scopus 로고    scopus 로고
    • Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomized, active-controlled, phase 3 non-inferiority trial
    • Eron JJ Jr, Rockstroh JK, Reynes J et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomized, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11: 907-15.
    • (2011) Lancet Infect Dis , vol.11 , pp. 907-915
    • Eron Jr., J.J.1    Rockstroh, J.K.2    Reynes, J.3
  • 22
    • 84255190565 scopus 로고    scopus 로고
    • Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results
    • Reynes J, Lawal A, Pulido F et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. HIV Clin Trials 2011; 12: 255-67.
    • (2011) HIV Clin Trials , vol.12 , pp. 255-267
    • Reynes, J.1    Lawal, A.2    Pulido, F.3
  • 23
    • 79251630271 scopus 로고    scopus 로고
    • A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial
    • Young B, Vanig T, Dejesus E et al. A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials 2010; 11: 260-9.
    • (2010) HIV Clin Trials , vol.11 , pp. 260-269
    • Young, B.1    Vanig, T.2    Dejesus, E.3
  • 24
    • 72849119170 scopus 로고    scopus 로고
    • High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: results of the ANRS 139 TRIO trial
    • Yazdanpanah Y, Fagard C, Descamps D et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49: 1441-9.
    • (2009) Clin Infect Dis , vol.49 , pp. 1441-1449
    • Yazdanpanah, Y.1    Fagard, C.2    Descamps, D.3
  • 25
    • 80051693755 scopus 로고    scopus 로고
    • Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial
    • Gallien S, Braun J, Delaugerre C et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 2011; 66: 2099-106.
    • (2011) J Antimicrob Chemother , vol.66 , pp. 2099-2106
    • Gallien, S.1    Braun, J.2    Delaugerre, C.3
  • 26
    • 84872422631 scopus 로고    scopus 로고
    • Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study
    • Abstract P111, International AIDS Society, Geneva, Switzerland, Glasgow, UK
    • Madeddu G, Soddu V, Ricci E et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study. In: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2010. Abstract P111, p. 71. International AIDS Society, Geneva, Switzerland.
    • (2010) Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection , pp. 71
    • Madeddu, G.1    Soddu, V.2    Ricci, E.3
  • 27
    • 77956646683 scopus 로고    scopus 로고
    • Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
    • Lennox JL, Dejesus E, Berger DS et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 39-48.
    • (2010) J Acquir Immune Defic Syndr , vol.55 , pp. 39-48
    • Lennox, J.L.1    Dejesus, E.2    Berger, D.S.3
  • 28
    • 77954257512 scopus 로고    scopus 로고
    • Raltegravir: the evidence of its therapeutic value in HIV-1 infection
    • Ramkumar K, Neamati N. Raltegravir: the evidence of its therapeutic value in HIV-1 infection. Core Evid 2010; 4: 131-47.
    • (2010) Core Evid , vol.4 , pp. 131-147
    • Ramkumar, K.1    Neamati, N.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.